BeyondSpring swings to Q3 net income of $50.49 million
BYSI•BeyondSpring reported third-quarter net income attributable to shareholders of $50.79 million, including a $53.67 million gain on the sale of subsidiary interests. Cash, cash equivalents and short-term investments fell 85% to $580,000 at September 30.
1. Quarterly results
BeyondSpring swung to third-quarter net income attributable to shareholders of $50.79 million from a loss a year earlier. Results included a $53.67 million gain on the sale of subsidiary interests. Cash, cash equivalents and short-term investments fell 85% to $580,000 at September 30 from December 31, 2025.
2. Drug development
The FDA granted Fast Track designation to Plinabulin with docetaxel for previously treated non-squamous lung cancer without actionable genomic alterations. A completed transaction with Biolin provides funding support for approximately half of DUBLIN-4's planned 442-patient enrollment.
